Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 724 entries
Sorted by: Best Match Show Resources per page
Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Castrillo A, Cardoso M, Rouse L.
PMID: 23637649
Transfus Med Hemother. 2013 Feb;40(1):44-8. doi: 10.1159/000345679. Epub 2013 Jan 03.

BACKGROUND: The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet light and is currently approved and used in Europe for the treatment of platelets and plasma. Mirasol treatment is intended to reduce the infectious pathogen load and...

Cite
Castrillo A, Cardoso M, Rouse L. Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system. Transfus Med Hemother. 2013;40(1):44-8doi: 10.1159/000345679.
Castrillo, A., Cardoso, M., & Rouse, L. (2013). Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40(1), 44-8. https://doi.org/10.1159/000345679
Castrillo, Azucena, et al. "Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 40,1 (2013): 44-8. doi: https://doi.org/10.1159/000345679
Castrillo A, Cardoso M, Rouse L. Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system. Transfus Med Hemother. 2013 Feb;40(1):44-8. doi: 10.1159/000345679. Epub 2013 Jan 03. PMID: 23637649; PMCID: PMC3635978.
Copy Download .nbib Format: NLM
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Gehrie EA, Tormey CA.
PMID: 25670929
Transfus Med Hemother. 2014 Nov;41(6):420-9. doi: 10.1159/000369109. Epub 2014 Nov 17.

In the context of transfusion medicine, alloimmunization most often refers to the development of antibodies to non-ABO red blood cell (RBC) antigens following pregnancy, transfusion, or transplantation. The development of RBC alloantibodies can have important clinical consequences, particularly in...

Cite
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfus Med Hemother. 2014;41(6):420-9doi: 10.1159/000369109.
Gehrie, E. A., & Tormey, C. A. (2014). The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 41(6), 420-9. https://doi.org/10.1159/000369109
Gehrie, Eric A, and Tormey, Christopher A. "The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 41,6 (2014): 420-9. doi: https://doi.org/10.1159/000369109
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfus Med Hemother. 2014 Nov;41(6):420-9. doi: 10.1159/000369109. Epub 2014 Nov 17. PMID: 25670929; PMCID: PMC4280450.
Copy Download .nbib Format: NLM
Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Gowland P, Fontana S, Stolz M, Andina N, Niederhauser C.
PMID: 27403092
Transfus Med Hemother. 2016 May;43(3):198-202. doi: 10.1159/000445195. Epub 2016 May 03.

BACKGROUND: Pathogen reduction methods for blood components are effective for a large number of viruses though less against small, non-enveloped viruses such as Parvovirus B19 (B19V). This article describes the passive transmission by transfusion of two B19V-contaminated pooled platelet...

Cite
Gowland P, Fontana S, Stolz M, et al. Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate. Transfus Med Hemother. 2016;43(3):198-202doi: 10.1159/000445195.
Gowland, P., Fontana, S., Stolz, M., Andina, N., & Niederhauser, C. (2016). Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(3), 198-202. https://doi.org/10.1159/000445195
Gowland, Peter, et al. "Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,3 (2016): 198-202. doi: https://doi.org/10.1159/000445195
Gowland P, Fontana S, Stolz M, Andina N, Niederhauser C. Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate. Transfus Med Hemother. 2016 May;43(3):198-202. doi: 10.1159/000445195. Epub 2016 May 03. PMID: 27403092; PMCID: PMC4924464.
Copy Download .nbib Format: NLM
Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Zolt SD, Thermann R, Bangsow T, Pichl L, Müller B, Jork C, Weber-Schehl M, Hedges D, Schupp I, Unverzagt P, de Rue K, Roth WK.
PMID: 27403090
Transfus Med Hemother. 2016 May;43(3):183-9. doi: 10.1159/000446290. Epub 2016 May 11.

BACKGROUND: Blood product safety was significantly improved by the introduction of NAT testing in the late 1990s, resulting in a strong decrease of transfusion-transmitted infections (TTIs). Due to the occurrence of HIV-1 NAT test failures as a consequence of...

Cite
Zolt SD, Thermann R, Bangsow T, et al. Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres. Transfus Med Hemother. 2016;43(3):183-9doi: 10.1159/000446290.
Zolt, S. D., Thermann, R., Bangsow, T., Pichl, L., Müller, B., Jork, C., Weber-Schehl, M., Hedges, D., Schupp, I., Unverzagt, P., de Rue, K., & Roth, W. K. (2016). Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(3), 183-9. https://doi.org/10.1159/000446290
Zolt, Silke De, et al. "Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,3 (2016): 183-9. doi: https://doi.org/10.1159/000446290
Zolt SD, Thermann R, Bangsow T, Pichl L, Müller B, Jork C, Weber-Schehl M, Hedges D, Schupp I, Unverzagt P, de Rue K, Roth WK. Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres. Transfus Med Hemother. 2016 May;43(3):183-9. doi: 10.1159/000446290. Epub 2016 May 11. PMID: 27403090; PMCID: PMC4924456.
Copy Download .nbib Format: NLM
Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Kzhyshkowska J, Gudima A, Moganti K, Gratchev A, Orekhov A.
PMID: 27226789
Transfus Med Hemother. 2016 Mar;43(2):66-77. doi: 10.1159/000444943. Epub 2016 Mar 15.

Low-grade chronic inflammation underlies the development of the most dangerous cardiometabolic disorders including type 2 diabetes and its vascular complications. In contrast to acute inflammation induced by bacteria and viruses, chronic inflammation can be driven by abnormal reaction to...

Cite
Kzhyshkowska J, Gudima A, Moganti K, et al. Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfus Med Hemother. 2016;43(2):66-77doi: 10.1159/000444943.
Kzhyshkowska, J., Gudima, A., Moganti, K., Gratchev, A., & Orekhov, A. (2016). Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(2), 66-77. https://doi.org/10.1159/000444943
Kzhyshkowska, Julia, et al. "Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,2 (2016): 66-77. doi: https://doi.org/10.1159/000444943
Kzhyshkowska J, Gudima A, Moganti K, Gratchev A, Orekhov A. Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfus Med Hemother. 2016 Mar;43(2):66-77. doi: 10.1159/000444943. Epub 2016 Mar 15. PMID: 27226789; PMCID: PMC4872050.
Copy Download .nbib Format: NLM
Zika Virus (ZIKV).

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

[No authors listed]
PMID: 27994533
Transfus Med Hemother. 2016 Nov;43(6):436-446. doi: 10.1159/000447782. Epub 2016 Oct 14.

No abstract available.

Cite
Zika Virus (ZIKV). Transfus Med Hemother. 2016;43(6):436-446doi: 10.1159/000447782.
(2016). Zika Virus (ZIKV). Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(6), 436-446. https://doi.org/10.1159/000447782
"Zika Virus (ZIKV)." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,6 (2016): 436-446. doi: https://doi.org/10.1159/000447782
Zika Virus (ZIKV). Transfus Med Hemother. 2016 Nov;43(6):436-446. doi: 10.1159/000447782. Epub 2016 Oct 14. PMID: 27994533; PMCID: PMC5159718.
Copy Download .nbib Format: NLM
Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Juhl D, Knobloch JK, Görg S, Hennig H.
PMID: 27022321
Transfus Med Hemother. 2016 Jan;43(1):37-43. doi: 10.1159/000441676. Epub 2015 Nov 04.

OBJECTIVE: Testing for antibodies against hepatitis B core antigen (anti-HBc) was introduced to detect blood donors suffering from occult hepatitis B infection. Confirmation of specification of reactive results in the anti-HBc screening assay is still a challenge for blood...

Cite
Juhl D, Knobloch JK, Görg S, et al. Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors. Transfus Med Hemother. 2015;43(1):37-43doi: 10.1159/000441676.
Juhl, D., Knobloch, J. K., Görg, S., & Hennig, H. (2016). Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(1), 37-43. https://doi.org/10.1159/000441676
Juhl, David, et al. "Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,1 (2016): 37-43. doi: https://doi.org/10.1159/000441676
Juhl D, Knobloch JK, Görg S, Hennig H. Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors. Transfus Med Hemother. 2016 Jan;43(1):37-43. doi: 10.1159/000441676. Epub 2015 Nov 04. PMID: 27022321; PMCID: PMC4797462.
Copy Download .nbib Format: NLM
A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Ries J, Komarek A, Gottschalk J, Brand B, Amsler L, Jutzi M, Frey BM.
PMID: 27994528
Transfus Med Hemother. 2016 Nov;43(6):415-417. doi: 10.1159/000446264. Epub 2016 Nov 04.

BACKGROUND: Transfusion-transmitted Chagas disease has been reported from endemic countries in Latin America. Switzerland is a non-endemic country but high prevalence of antibodies against METHODS: Between January 2013 and July 2015, 1 out of 1,183 at-risk donors, tested at...

Cite
Ries J, Komarek A, Gottschalk J, et al. A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland. Transfus Med Hemother. 2016;43(6):415-417doi: 10.1159/000446264.
Ries, J., Komarek, A., Gottschalk, J., Brand, B., Amsler, L., Jutzi, M., & Frey, B. M. (2016). A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(6), 415-417. https://doi.org/10.1159/000446264
Ries, Judith, et al. "A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,6 (2016): 415-417. doi: https://doi.org/10.1159/000446264
Ries J, Komarek A, Gottschalk J, Brand B, Amsler L, Jutzi M, Frey BM. A Case of Possible Chagas Transmission by Blood Transfusion in Switzerland. Transfus Med Hemother. 2016 Nov;43(6):415-417. doi: 10.1159/000446264. Epub 2016 Nov 04. PMID: 27994528; PMCID: PMC5159710.
Copy Download .nbib Format: NLM
Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Yamamoto K, Doki N, Senoo Y, Najima Y, Kobayashi T, Kakihana K, Haraguchi K, Okuyama Y, Sakamaki H, Ohashi K.
PMID: 27994532
Transfus Med Hemother. 2016 Nov;43(6):433-435. doi: 10.1159/000446814. Epub 2016 Oct 18.

BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is widely used to mobilize peripheral blood stem cells (PBSCs) in healthy donors. A few reports have shown that some healthy donors developed acute respiratory distress syndrome or capillary leak syndrome after more than...

Cite
Yamamoto K, Doki N, Senoo Y, et al. Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor. Transfus Med Hemother. 2016;43(6):433-435doi: 10.1159/000446814.
Yamamoto, K., Doki, N., Senoo, Y., Najima, Y., Kobayashi, T., Kakihana, K., Haraguchi, K., Okuyama, Y., Sakamaki, H., & Ohashi, K. (2016). Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(6), 433-435. https://doi.org/10.1159/000446814
Yamamoto, Keita, et al. "Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,6 (2016): 433-435. doi: https://doi.org/10.1159/000446814
Yamamoto K, Doki N, Senoo Y, Najima Y, Kobayashi T, Kakihana K, Haraguchi K, Okuyama Y, Sakamaki H, Ohashi K. Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor. Transfus Med Hemother. 2016 Nov;43(6):433-435. doi: 10.1159/000446814. Epub 2016 Oct 18. PMID: 27994532; PMCID: PMC5159728.
Copy Download .nbib Format: NLM
Blood Bag Plasticizers Influence Red Blood Cell Vesiculation Rate without Altering the Lipid Composition of the Vesicles.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Bicalho B, Serrano K, Dos Santos Pereira A, Devine DV, Acker JP.
PMID: 27022319
Transfus Med Hemother. 2016 Jan;43(1):19-26. doi: 10.1159/000441639. Epub 2015 Oct 29.

BACKGROUND: Polyvinyl chloride (PVC) plasticized with di(2-ethylhexyl) phthalate (DEHP) is commonly used for blood collection and storage. DEHP has protective effects on RBC membranes, but is also a toxin.METHODS: A paired study was conducted to investigate the influence of...

Cite
Bicalho B, Serrano K, Dos Santos Pereira A, et al. Blood Bag Plasticizers Influence Red Blood Cell Vesiculation Rate without Altering the Lipid Composition of the Vesicles. Transfus Med Hemother. 2015;43(1):19-26doi: 10.1159/000441639.
Bicalho, B., Serrano, K., Dos Santos Pereira, A., Devine, D. V., & Acker, J. P. (2016). Blood Bag Plasticizers Influence Red Blood Cell Vesiculation Rate without Altering the Lipid Composition of the Vesicles. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 43(1), 19-26. https://doi.org/10.1159/000441639
Bicalho, Beatriz, et al. "Blood Bag Plasticizers Influence Red Blood Cell Vesiculation Rate without Altering the Lipid Composition of the Vesicles." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 43,1 (2016): 19-26. doi: https://doi.org/10.1159/000441639
Bicalho B, Serrano K, Dos Santos Pereira A, Devine DV, Acker JP. Blood Bag Plasticizers Influence Red Blood Cell Vesiculation Rate without Altering the Lipid Composition of the Vesicles. Transfus Med Hemother. 2016 Jan;43(1):19-26. doi: 10.1159/000441639. Epub 2015 Oct 29. PMID: 27022319; PMCID: PMC4797466.
Copy Download .nbib Format: NLM
Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Humpe A, Peipp M.
PMID: 29070973
Transfus Med Hemother. 2017 Sep;44(5):290-291. doi: 10.1159/000479617. Epub 2017 Sep 13.

No abstract available.

Cite
Humpe A, Peipp M. Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design. Transfus Med Hemother. 2017;44(5):290-291doi: 10.1159/000479617.
Humpe, A., & Peipp, M. (2017). Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 44(5), 290-291. https://doi.org/10.1159/000479617
Humpe, Andreas, and Peipp, Matthias. "Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 44,5 (2017): 290-291. doi: https://doi.org/10.1159/000479617
Humpe A, Peipp M. Antibody Engineering - Tailor-Made Next Generation Antibodies by Molecular Design. Transfus Med Hemother. 2017 Sep;44(5):290-291. doi: 10.1159/000479617. Epub 2017 Sep 13. PMID: 29070973; PMCID: PMC5649259.
Copy Download .nbib Format: NLM
Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Padayachee ER, Biteghe FAN, Malindi Z, Bauerschlag D, Barth S.
PMID: 29070975
Transfus Med Hemother. 2017 Sep;44(5):303-310. doi: 10.1159/000479979. Epub 2017 Sep 11.

Considerable research efforts have been dedicated to understanding ovarian and breast cancer mechanisms, but there has been little progress translating the research into effective clinical applications. Hence, personalized/precision medicine has emerged because of its potential to improve the accuracy...

Cite
Padayachee ER, Biteghe FAN, Malindi Z, et al. Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. Transfus Med Hemother. 2017;44(5):303-310doi: 10.1159/000479979.
Padayachee, E. R., Biteghe, F. A. N., Malindi, Z., Bauerschlag, D., & Barth, S. (2017). Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 44(5), 303-310. https://doi.org/10.1159/000479979
Padayachee, Eden R, et al. "Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 44,5 (2017): 303-310. doi: https://doi.org/10.1159/000479979
Padayachee ER, Biteghe FAN, Malindi Z, Bauerschlag D, Barth S. Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. Transfus Med Hemother. 2017 Sep;44(5):303-310. doi: 10.1159/000479979. Epub 2017 Sep 11. PMID: 29070975; PMCID: PMC5649269.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 724 entries